z-logo
open-access-imgOpen Access
Clinical Experience with Linezolid for the Treatment ofNocardiaInfection
Author(s) -
Edina Moylett,
Susan E. Pacheco,
Barbara A. BrownElliott,
Tracy Perry,
E. Stephen Buescher,
Mary C. Birmingham,
Jerome J. Schentag,
Joseph F. Gimbel,
Aaron A. Apodaca,
Margot A. Schwartz,
Robert M. Rakita,
Richard J. Wallace
Publication year - 2003
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/345907
Subject(s) - linezolid , medicine , discontinuation , nocardiosis , nocardia , antibiotics , regimen , pharmacotherapy , surgery , microbiology and biotechnology , bacteria , staphylococcus aureus , vancomycin , biology , genetics
Linezolid is an oxazolidinone that has activity against most gram-positive bacteria, including in vitro activity against all Nocardia species and strains. We describe 6 clinical cases of nocardiosis that were successfully treated with linezolid. Two patients had underlying X-linked chronic granulomatous disease, and 2 patients were receiving chronic corticosteroid therapy. Four of 6 patients had disseminated disease, and 2 of these 4 patients had multiple brain abscesses. Four patients primarily received monotherapy; for the fifth patient, linezolid was added to a failing multiple-drug regimen, and, for the sixth patient, it was used as part of combination therapy. All 6 patients were successfully treated, although 1 patient had a presumed relapse of central nervous system infection after premature discontinuation of the drug. Linezolid appears to be an effective alternative for the treatment of nocardiosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom